Alivus Life Sciences reported a revenue of ₹5,880 Mn for Q2 FY26, a 16% increase YoY. Non-GPL business grew by 39.7% YoY. EBITDA margins reached 33%. The company generated a free cash flow of ₹1,477 Mn, resulting in cash and equivalents of ₹6,526 Mn. Alivus is confident about delivering a stronger performance in the second half of the year.
Q2 FY26 Financial Highlights
Alivus Life Sciences announced its financial results for Q2 FY26, demonstrating strong performance across key metrics:
- Revenue: ₹5,880 Mn (Up 16% YoY)
- EBITDA: ₹1,939 Mn (Up 35.7% YoY)
- PAT: ₹1,301 Mn (Up 36.5% YoY)
The company’s gross margin was 57.7%, a 260 bps increase QoQ and a 210 bps increase YoY. This was driven by new launches and a favorable product mix.
Segment Performance
The non-GPL business showed robust growth, increasing by 39.7% YoY, driven by strong demand across key geographies.
- Generic API Revenue: Increased by 15.3% YoY.
- CDMO Revenue: Increased by 15.8% YoY.
- GPL Business: ₹1,437 Mn (Down 23.9% YoY).
- Non-GPL Business: ₹4,443 Mn (Up 39.7% YoY).
Key Financial Indicators
- ROICE: Tracking at approximately 29%.
- FATR: 2.4 times.
- Cash and Cash Equivalents: ₹6,526 Mn as of September 30, 2025.
Strategic Initiatives
Alivus is focused on several strategic initiatives to drive future growth, including new product launches, geographical expansion, and pursuing second source opportunities. The company is also working on capacity expansion projects, including a greenfield project in Solapur and expansions in Dahej and Ankleshwar.
Therapeutic and Market Mix
The regulated markets contributed 81% of revenue in Q2 FY26. Chronic therapies accounted for 69% of revenue.
Source: BSE
